AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00784680
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg, orally, once daily
Trial: NCT00784680
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg, orally, once daily
Trial: NCT00650689
Drug: Ezetimibe + Atorvastatin
RxNorm normalized name: atorvastatin / ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
Trial: NCT00650689
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
Trial: NCT04164459
Drug: Xalost S
RxNorm normalized name: S-2
DrugBank: Racepinephrine (DB11124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop one times a day in study eye
Trial: NCT04164459
Drug: Xalatan
RxNorm normalized name: Xalatan
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop one times a day in study eye
Trial: NCT04164459
Drug: Taflotan-S
RxNorm normalized name: S-2
DrugBank: Racepinephrine (DB11124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop one times a day in study eye
Trial: NCT00603954
Drug: Conditioning regimen: TBI + Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Gy TBI, Fludarabine 90 mg/m²
Trial: NCT03191981
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
Trial: NCT03191981
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
Trial: NCT01548170
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One capsule of sunitinib 50 mg orally. Single dose
Trial: NCT01548170
Drug: Sunitinib and Ketoconazol
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
Trial: NCT01548170
Drug: Sunitiinb and Ketoconazol
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
Trial: NCT01548170
Drug: Sunitinib and Ketoconazol
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
Trial: NCT04474210
Drug: JNJ-56136379
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-56136379 tablets orally.
Trial: NCT01548170
Drug: Sunitinib and Ketoconazol
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
Trial: NCT02117752
Drug: dapsone gel
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patches containing dapsone gel will be applied to the skin.
Trial: NCT02117752
Drug: dapsone gel vehicle
RxNorm normalized name: dapsone Topical Gel
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patches containing dapsone gel vehicle will be applied to the skin.
Trial: NCT02117752
Drug: sodium lauryl sulfate
RxNorm normalized name: sodium lauryl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.
Trial: NCT02255162
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
Trial: NCT02255162
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
Trial: NCT02182856
Drug: Ipratropium bromide 500 µg/salbutamol sulphate 3 mg
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02182856
Drug: Ipratropium 500 µg
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02182856
Drug: Salbutamol sulphate 3 mg
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02182856
Drug: Salbutamol sulphate 6 mg
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02520726
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.
Trial: NCT02713126
Drug: Sodium Nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered orally or inhaled, 40 mg, taken every 4 hours or 3 times per day during waking hours for 12 weeks
Trial: NCT00084396
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00339586
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01110824
Drug: Enalapril and carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID
Trial: NCT01494922
Drug: EXC 001 (currently called PF-06473871)
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administered by injection at four different times
Trial: NCT01189942
Drug: OMP-21M18
RxNorm normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first 6 participants will receive OMP21M18 2.5 mg/kg once every other week, the next 6 participants will receive 5 mg/kg once every other week, and the final 6 participants will receive 10 mg/kg once every other week. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.
Trial: NCT01094184
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.
Trial: NCT01094184
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
Trial: NCT01094184
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
Trial: NCT03912831
Drug: KITE-439
RxNorm normalized name: KITE-222
DrugBank: KITE-222 (DB17195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single infusion of E7 TCR T cells (KITE-439).
Trial: NCT03912831
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously.
Trial: NCT03912831
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously.
Trial: NCT01460667
Drug: IV normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline IV, every 6 hours over 30 hours.
Trial: NCT00490100
Drug: Increlex
RxNorm normalized name: Increlex
DrugBank: Mecasermin (DB01277)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01657604
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
Trial: NCT00918385
Drug: Nilutamide
RxNorm normalized name: Nilutamide
DrugBank: Nilutamide (DB00665)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.
Trial: NCT00918385
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
Trial: NCT00322881
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00322881
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01985542
Drug: birch pollen subcutaneous immunotherapy
RxNorm normalized name: cherry birch pollen extract
DrugBank: Betula lenta pollen (DB10352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: birch pollen subcutaneous immunotherapy
Trial: NCT02912208
Drug: Eltrombopag/Revolade
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
Trial: NCT01255670
Drug: penicillin and metronidazole in peritonsillar abscess
RxNorm normalized name: metronidazole and diloxanide
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
Trial: NCT03740048
Drug: Patiromer Oral Product
RxNorm normalized name: patiromer Oral Product
DrugBank: Patiromer (DB09263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.
Trial: NCT00000214
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02703558
Drug: Phenazopyridine
RxNorm normalized name: Phenazopyridine
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02703558
Drug: Fluorescein
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01985295
Drug: pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.
Trial: NCT04570592
Drug: Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparing PONV incidences in both arms
Trial: NCT04570592
Drug: Granisetron 1 Mg/mL Intravenous Solution
RxNorm normalized name: granisetron 1 mg/mL intravenous solution
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparing PONV incidences in both arms
Trial: NCT02886195
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg/m2 ivgtt d1, per three weeks
Trial: NCT02886195
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80mg/m2 ivgtt d1, per three weeks
Trial: NCT02886195
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg po. every day
Trial: NCT02245555
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00756106
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide is administered according to standard of care practice guidelines. Dosing may be modified at the discretion of the treating investigator.
Trial: NCT02023892
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02055872
Drug: Intravenous albumin
RxNorm normalized name: albumin human, USP Injection [Albuminar]
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03261336
Drug: Calcitriol, Ketoconazole, Hydrocortisone
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.5 mcg caplets) given in escalating doses, orally QD X3 consecutive days every week Ketoconazole, 200 mg tablets, 2 tablets orally TID Hydrocortisone 20mg AM, 10mg PM orally starting in the evening before the first dose of Calcitriol
Trial: NCT03568994
Drug: Atovaquone
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive standard of care MRC based Induction chemotherapy (such as ADE 10+3+5 with daily atovaquone dosing starting on day 6. In order to accommodate potential drug shortages modifications to ADE 10+3+5 that retain the MRC based induction backbone regimen of DA are allowed (see second Arm). These include but are not limited to substitution of etopophos for etoposide, exclusion of etoposide, use of CPX-351 (VYXEOS (daunorubicin and cytarabine) liposome) only, and daunorubicin and cytarabine (DA) + gemtuzumab ozogamicin (GO).~Patients will be monitored for adherence to and tolerance of daily dosing of atovaquone. Peripheral blood (PB) and bone marrow plasma samples will be obtained to measure atovaquone concentrations.
Trial: NCT03568994
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As part of routine Induction 1 chemotherapy (ADE 10+3+5)
Trial: NCT03568994
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As part of routine Induction 1 chemotherapy (ADE 10+3+5)
Trial: NCT03568994
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As part of routine Induction 1 chemotherapy (ADE 10+3+5)
Trial: NCT03568994
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As part of routine Induction 1 chemotherapy(DA 3+10 + GO)
Trial: NCT02124668
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT02462044
Drug: 240 mg Iodine
RxNorm normalized name: iohexol 240 mg iodine/mL INJECTION KIT
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02462044
Drug: 300 mg Iodine
RxNorm normalized name: iohexol 300 mg iodine/mL INTRAVEN VIAL (ML)
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02462044
Drug: 370 mg Iodine
RxNorm normalized name: iopamidol 370 mg iodine/mL (76 %) INTRAVEN KIT
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02506894
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: magnesium sulfate will be given for 24 hours
Trial: NCT00292942
Drug: Intravenous Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Three doses of Intravenous Artesunate drug at 2, 4, or 8 mg/kg in diluent Phosphate Buffer (0.3 M, pH 8.1)
Trial: NCT01893541
Drug: PROPRANOLOL
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
Trial: NCT00435916
Drug: SGN-40
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12.
Trial: NCT01258777
Drug: 400 mg golimumab or placebo
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of 400 mg subcutaneously
Trial: NCT01258777
Drug: 200 mg golimumab or placebo
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of 200 mg subcutaneously
Trial: NCT02774460
Drug: Hydrochlorthiazide®
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
Trial: NCT02774460
Drug: Treatment Y
RxNorm normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
Trial: NCT02411630
Drug: Emtricitabine/tenofovir disoproxil
RxNorm normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.~The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed.
Trial: NCT03201796
Drug: Prulifloxacin 600 mg
RxNorm normalized name: Orbifloxacin
DrugBank: Prulifloxacin (DB11892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
Trial: NCT03201796
Drug: Levofloxacin 500mg
RxNorm normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
Trial: NCT03613740
Drug: Fucoxanthin
RxNorm normalized name: Fucoxanthin
DrugBank: Fucoxanthin (DB15462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention will be administered 30 minutes before breakfast.
Trial: NCT02682485
Drug: Cipro, metronidazole, neomycin combo
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
Trial: NCT02682485
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
Trial: NCT00268723
Drug: Levalbuterol tartrate HFA MDI
RxNorm normalized name: Levalbuterol Tartrate
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levalbuterol MDI 90 mcg QID